Cuorips, Inc. engages in the development and commercialization of induced pluripotent stem cells (iPS) derived cardiomyocyte sheets. It handles research, development, manufacture, and sales of cellular and tissue-based products and cell processing products. The firm also offers contract development and manufacturing services and consulting services of cellular and tissue-based products and cell processing products. The company was founded on March 21, 2017 and is headquartered in Tokyo, Japan.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company